3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Glioblastoma
3
Recurrence
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Gliosarcoma
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Carboplatin
158
Paclitaxel
152
Bevacizumab
85
Gemcitabine
48
liposomal doxorubicin
47
Taxes
47
Topotecan
41
Cisplatin
34
pembrolizumab
33
Cyclophosphamide
27
olaparib
25
Immunoglobulin G
24
Disulfides
24
Specimen Handling
20
Docetaxel
20
Drug Therapy
19
Magnetic Resonance Spectroscopy
17
niraparib
16
Doxorubicin
16
Biopsy
15
mirvetuximab soravtansine
14
Hyperthermic Intraperitoneal Chemotherapy
13
rucaparib
12
Nivolumab
12
Cytoreduction Surgical Procedures
10
Albumin-Bound Paclitaxel
10
veliparib
9
Platinum
9
Chemotherapy, Adjuvant
9
130-nm albumin-bound paclitaxel
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Fallopian Tube Neoplasms
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts